Business Context and Reporting Period
This Form 6-K filing by NLS Pharmaceutics Ltd. (also referenced as Newcelx Ltd. in metadata) covers the month of August 2024, with a report date of August 26, 2024. The registrant is a foreign private issuer headquartered in Zurich, Switzerland. The primary purpose of this filing is to announce two Extraordinary Shareholders' Meetings scheduled for September 18, 2024.
Revenue, Profit, Cash Flow, and Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a procedural notice regarding shareholder meetings and does not contain financial statements or operational metrics.
Material Changes Versus Prior Period
No material financial changes versus a prior comparable period are disclosed in this document. The filing focuses solely on corporate governance actions regarding the upcoming shareholder meetings.
Guidance, Outlook, and Management Commentary
There is no financial guidance, outlook, or management commentary regarding business performance in this filing. The document incorporates by reference the Notice of Meeting and Proxy Card for the September 18, 2024 meetings. Only shareholders of record as of the close of business on August 23, 2024, are entitled to vote.
Key Facts for Investor Verification
- Meeting Date: Two Extraordinary Shareholders' Meetings are set for September 18, 2024.
- Record Date: Shareholders must hold common shares as of August 23, 2024, to vote.
- Document Reference: The Notice of Meeting and Proxy Card are attached as Exhibit 99.1.
- Registration Impact: This report is incorporated by reference into the company's Form F-3 Registration Statements (File Nos. 333-262489, 333-268690, and 333-269220).
- Financial Data: No financial results are included in this specific filing.